2025-06-11-Jefferies-命运治疗公司（FATE）_在欧洲抗风湿病联盟（EULAR）会议上公布的现货型CAR_-_T治疗狼疮的新前景数据_8页_105kb

Summary of Jefferies Equity Research Report on Fate Therapeutics (FATE)

Rating and Price Target:

• Jefferies rates Fate Therapeutics (FATE) as "Buy" with a price target of $8.00 per share (current price $1.67, potential upside of +379%). The price target is DCF-based and reflects positive clinical data.

Key Clinical Data:

• Encouraging lupus nephritis data presented at EULAR, including primary efficacy renal response (PERR) in three patients with flu-free conditioning. One patient maintained Doris remission at 1-year follow-up.
• Initial data from a no-conditioning cohort showed achievement of low lupus disease activity state (LLDAS) and sustained remission, supporting the off-the-shelf CAR-T therapy's efficacy.
• Overall, durability and reduced toxicity due to the company's iPSC platform were highlighted, with no dose-limiting toxicities or severe adverse events reported in the Phase I study.
• Safety profile is favorable across ~60 treated patients, with minimal CRS or GvHD, and potential for outpatient administration, enhancing commercial viability.

Company Overview:

• Fate Therapeutics is a biopharmaceutical company developing programmed cellular immunotherapies for cancer, immune disorders, and autoimmune diseases.
• The off-the-shelf platform reduces the need for lymphodepletion, potentially broadening applications for large indications like lupus.
• Current market cap is $255.8M, with equity research focusing on innovations in CAR-T therapy.

Future Plans and Expansion:

• The company aims to expand clinical sites to 10 in the summer and 20-25 by year-end, including enrollment in Phase I studies for additional lupus cohorts and diseases like AAV, IIM, and SSc.
• Plans include discussions with regulatory agencies for potential registrational strategies as early as next year, targeting commercialization of FT819.

Risks and Valuation Considerations:

• Key risks include clinical, regulatory, and commercial uncertainties, despite positive data.
• Valuation is driven by the potential of the off-the-shelf platform, but current sentiment and investor attention remain limited. The equity research notes overall low expectations for the stock, with concerns from analysts.